{
    "relation": [
        [
            "Feature key",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti"
        ],
        [
            "Position(s)",
            "10 \u2013 10",
            "25 \u2013 25",
            "81 \u2013 81",
            "218 \u2013 218",
            "218 \u2013 218",
            "222 \u2013 222",
            "223 \u2013 223",
            "223 \u2013 223",
            "225 \u2013 225",
            "263 \u2013 263"
        ],
        [
            "Length",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1"
        ],
        [
            "Description",
            "L \u2192 P Associated with higher bone mineral density and lower frequency of vertebral fractures in Japanese post-menopausal women. 3 Publications Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.2 \"Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells.\" Derynck R., Jarrett J.A., Chen E.Y., Eaton D.H., Bell J.R., Assoian R.K., Roberts A.B., Sporn M.B., Goeddel D.V. Nature 316:701-705(1985) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], VARIANTS PRO-10 AND PRO-25. Ref.22 \"Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women.\" Yamada Y., Miyauchi A., Goto J., Takagi Y., Okuizumi H., Kanematsu M., Hase M., Takai H., Harada A., Ikeda K. J. Bone Miner. Res. 13:1569-1576(1998) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT PRO-10. Ref.25 \"A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway.\" Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T., Matsumoto N., Ishikawa M., Niikawa N., Yoshiura K. J. Hum. Genet. 47:478-483(2002) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT PRO-10. Corresponds to variant rs1800470 [ dbSNP | Ensembl ].",
            "R \u2192 P.1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.2 \"Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells.\" Derynck R., Jarrett J.A., Chen E.Y., Eaton D.H., Bell J.R., Assoian R.K., Roberts A.B., Sporn M.B., Goeddel D.V. Nature 316:701-705(1985) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], VARIANTS PRO-10 AND PRO-25. Corresponds to variant rs1800471 [ dbSNP | Ensembl ].",
            "Y \u2192 H in CAEND; leads to TGF-beta-1 intracellular accumulation. 2 Publications Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.24 \"Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease.\" Janssens K., Gershoni-Baruch R., Guanabens N., Migone N., Ralston S., Bonduelle M., Lissens W., Van Maldergem L., Vanhoenacker F., Verbruggen L., Van Hul W. Nat. Genet. 26:273-275(2000) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CAEND HIS-81; CYS-218 AND ARG-225. Ref.26 \"Transforming growth factor-beta-1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein.\" Janssens K., ten Dijke P., Ralston S.H., Bergmann C., Van Hul W. J. Biol. Chem. 278:7718-7724(2003) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION OF VARIANTS CAEND HIS-81; CYS-218; ASP-222 AND ARG-225.",
            "R \u2192 C in CAEND; higher levels of active TGF-beta-1 in the culture medium; enhances osteoclast formation in vitro. 4 Publications Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.23 \"Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.\" Kinoshita A., Saito T., Tomita H., Makita Y., Yoshida K., Ghadami M., Yamada K., Kondo S., Ikegawa S., Nishimura G., Fukushima Y., Nakagomi T., Saito H., Sugimoto T., Kamegaya M., Hisa K., Murray J.C., Taniguchi N., Niikawa N., Yoshiura K. Nat. Genet. 26:19-20(2000) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CAEND CYS-218; HIS-218 AND ARG-225. Ref.24 \"Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease.\" Janssens K., Gershoni-Baruch R., Guanabens N., Migone N., Ralston S., Bonduelle M., Lissens W., Van Maldergem L., Vanhoenacker F., Verbruggen L., Van Hul W. Nat. Genet. 26:273-275(2000) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CAEND HIS-81; CYS-218 AND ARG-225. Ref.26 \"Transforming growth factor-beta-1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein.\" Janssens K., ten Dijke P., Ralston S.H., Bergmann C., Van Hul W. J. Biol. Chem. 278:7718-7724(2003) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION OF VARIANTS CAEND HIS-81; CYS-218; ASP-222 AND ARG-225. Ref.27 \"A mutation affecting the latency-associated peptide of TGFbeta1 in Camurati-Engelmann disease enhances osteoclast formation in vitro.\" McGowan N.W., MacPherson H., Janssens K., Van Hul W., Frith J.C., Fraser W.D., Ralston S.H., Helfrich M.H. J. Clin. Endocrinol. Metab. 88:3321-3326(2003) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION OF VARIANT CAEND CYS-218.",
            "R \u2192 H in CAEND. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.23 \"Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.\" Kinoshita A., Saito T., Tomita H., Makita Y., Yoshida K., Ghadami M., Yamada K., Kondo S., Ikegawa S., Nishimura G., Fukushima Y., Nakagomi T., Saito H., Sugimoto T., Kamegaya M., Hisa K., Murray J.C., Taniguchi N., Niikawa N., Yoshiura K. Nat. Genet. 26:19-20(2000) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CAEND CYS-218; HIS-218 AND ARG-225.",
            "H \u2192 D in CAEND; sporadic case; higher levels of active TGF-beta-1 in the culture medium. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.26 \"Transforming growth factor-beta-1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein.\" Janssens K., ten Dijke P., Ralston S.H., Bergmann C., Van Hul W. J. Biol. Chem. 278:7718-7724(2003) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION OF VARIANTS CAEND HIS-81; CYS-218; ASP-222 AND ARG-225.",
            "C \u2192 G in CAEND. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.28 \"TGFB1 mutations in four new families with Camurati-Engelmann disease: confirmation of independently arising LAP-domain-specific mutations.\" Kinoshita A., Fukumaki Y., Shirahama S., Miyahara A., Nishimura G., Haga N., Namba A., Ueda H., Hayashi H., Ikegawa S., Seidel J., Niikawa N., Yoshiura K. Am. J. Med. Genet. 127A:104-107(2004) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CAEND GLY-223 AND ARG-223.",
            "C \u2192 R in CAEND. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.28 \"TGFB1 mutations in four new families with Camurati-Engelmann disease: confirmation of independently arising LAP-domain-specific mutations.\" Kinoshita A., Fukumaki Y., Shirahama S., Miyahara A., Nishimura G., Haga N., Namba A., Ueda H., Hayashi H., Ikegawa S., Seidel J., Niikawa N., Yoshiura K. Am. J. Med. Genet. 127A:104-107(2004) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CAEND GLY-223 AND ARG-223.",
            "C \u2192 R in CAEND; higher levels of active TGF-beta-1 in the culture medium. 3 Publications Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.23 \"Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.\" Kinoshita A., Saito T., Tomita H., Makita Y., Yoshida K., Ghadami M., Yamada K., Kondo S., Ikegawa S., Nishimura G., Fukushima Y., Nakagomi T., Saito H., Sugimoto T., Kamegaya M., Hisa K., Murray J.C., Taniguchi N., Niikawa N., Yoshiura K. Nat. Genet. 26:19-20(2000) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CAEND CYS-218; HIS-218 AND ARG-225. Ref.24 \"Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease.\" Janssens K., Gershoni-Baruch R., Guanabens N., Migone N., Ralston S., Bonduelle M., Lissens W., Van Maldergem L., Vanhoenacker F., Verbruggen L., Van Hul W. Nat. Genet. 26:273-275(2000) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CAEND HIS-81; CYS-218 AND ARG-225. Ref.26 \"Transforming growth factor-beta-1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein.\" Janssens K., ten Dijke P., Ralston S.H., Bergmann C., Van Hul W. J. Biol. Chem. 278:7718-7724(2003) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION OF VARIANTS CAEND HIS-81; CYS-218; ASP-222 AND ARG-225.",
            "T \u2192 I. Corresponds to variant rs1800472 [ dbSNP | Ensembl ]."
        ],
        [
            "Graphical view",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            ""
        ],
        [
            "Feature identifier",
            "VAR_016171",
            "VAR_016172",
            "VAR_017607",
            "VAR_017608",
            "VAR_017609",
            "VAR_017610",
            "VAR_067303",
            "VAR_067304",
            "VAR_017611",
            "VAR_016173"
        ],
        [
            "Actions",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            ""
        ]
    ],
    "pageTitle": "TGFB1 - Transforming growth factor beta-1 precursor - Homo sapiens (Human)",
    "title": "",
    "url": "http://www.uniprot.org/uniprot/P01137",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988718.8/warc/CC-MAIN-20150728002308-00260-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 800701655,
    "recordOffset": 800641126,
    "tableOrientation": "HORIZONTAL",
    "lastModified": "Wed, 22 Jul 2015 00:00:00 GMT",
    "textBeforeTable": "Natural variant In post-menopausal Japanese women, the frequency of Leu-10 is higher in subjects with osteoporosis than in controls. <p>Provides information on polymorphic variants. If the variant is associated with a disease state, the description of the latter can be found in the <a href=\"/manual/involvement_in_disease\">\u2018Involvement in disease\u2019</a> subsection.</p><p><a href='../manual/polymorphism' target='_top'>More...</a></p>Polymorphismi R \u2192 RR in CAA26580 (PubMed:3861940).Curated 1 159\u00a0\u2013\u00a0159 <p>Reports difference(s) between the canonical sequence (displayed by default in the entry) and the different sequence submissions merged in the entry. These various submissions may originate from different sequencing projects, different types of experiments, or different biological samples. Sequence conflicts are usually of unknown origin.</p><p><a href='../manual/conflict' target='_top'>More...</a></p>Sequence conflicti Actions Feature identifier Graphical view Description Length Position(s) Feature key Experimental InfoBLASTProtParamProtScaleCompute pI/MWPeptideMassPeptideCutterGO <p>The checksum is a form of redundancy check that is calculated from the sequence. It is useful for tracking sequence updates.</p> <p>It should be noted that while, in theory, two different",
    "textAfterTable": "Sequence databases Select the link destinations: EMBL nucleotide sequence database<br/><a href='/database/22'>More..</a>EMBLi GenBank nucleotide sequence database<br/><a href='/database/28'>More..</a>GenBanki DNA Data Bank of Japan; a nucleotide sequence database<br/><a href='/database/14'>More..</a>DDBJi Links Updated X05839 , X05840, X05843, X05844, X05849, X05850 Genomic DNA. Translation: CAA29283.1. X02812 mRNA. Translation: CAA26580.1. BT007245 mRNA. Translation: AAP35909.1. AK291907 mRNA. Translation: BAF84596.1. CH471126 Genomic DNA. Translation: EAW57032.1. BC001180 mRNA. Translation: AAH01180.1. BC000125 mRNA. Translation: AAH00125.1. BC022242 mRNA. Translation: AAH22242.1.",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}